Search company, investor...


Founded Year



Series B | Alive

Total Raised




Last Raised

$20M | 16 yrs ago

About Aquest

Aquest offers automation solutions for the semiconductor manufacturing industry

Headquarters Location

683 West Maude Avenue

Sunnyvale, California, 94085,

United States


Missing: Aquest's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aquest's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aquest

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aquest is included in 1 Expert Collection, including Semiconductors, Chips, and Advanced Electronics.


Semiconductors, Chips, and Advanced Electronics

6,250 items

Companies in this collection develop everything from microprocessors to flash memory, integrated circuits specifically for quantum computing and artificial intelligence to OLED for displays, massive production fabs to circuit design firms, and everything in between.

Latest Aquest News

Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Aquest

Nov 1, 2022

Benzinga By Globe Newswire Reported positive data from EPIPHAST II trial comparing AQST-109 (epinephrine sublingual film) to EpiPen 0.3mg (single dose) and AQST-109 to epi 0.3mg IM injection (repeat dose) Scheduled End-of-Phase 2 (EoP2) meeting with FDA on AQST-109 for fourth quarter 2022 Generated over $25 million in near-term non-dilutive funding through multiple transactions Announces strategic decision to explore US out-licensing opportunities for Libervant (diazepam buccal film) Confirms full-year revenue and earnings guidance Hosts investment community conference call on November 2, 2022 AD AD WARREN, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. AQST, a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying complex delivery methods, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business. We have made significant progress over the last few months in streamlining our business, reducing expenses, and creating a path to an improved financial position, while continuing to rapidly advance our lead asset, AQST-109, said Daniel Barber, Chief Executive Officer of Aquestive. We continue to believe in the real-world utility of epinephrine sublingual film and look forward to reviewing the data and pivotal program plan with the FDA in our upcoming EoP2 meeting. At the same time, we continue to engage with the FDA on Libervant and are prioritizing the exploration of out-licensing this important product for North America. In the meantime, our manufacturing business continues to generate strong results, thereby allowing us to focus on reducing and potentially refinancing our corporate debt as we progress into 2023.

Aquest Frequently Asked Questions (FAQ)

  • When was Aquest founded?

    Aquest was founded in 2004.

  • Where is Aquest's headquarters?

    Aquest's headquarters is located at 683 West Maude Avenue, Sunnyvale.

  • What is Aquest's latest funding round?

    Aquest's latest funding round is Series B.

  • How much did Aquest raise?

    Aquest raised a total of $20M.

  • Who are the investors of Aquest?

    Investors of Aquest include Menlo Ventures, Walden International, Global Catalyst Partners and Pinnacle Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.